Cosmo Pharmaceuticals N.V.
CMOPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1B
Close$
$35.02
49.8% downside
Current Fair Value
49.8% downsideOvervalued by 49.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.07 Billion |
| Annual dividend | $2.46 |
| Dividend yield | 3.66% |
| Earnings per Share | $-0.23 |
| Beta | 1.49 |
| Outstanding Shares | 17,042,708 |
Return
| Return on Equity | 8.62% |
|---|---|
| Return on Assets | 7.03% |
| Return on Invested Capital | 7.65% |
Valuation & Multiples
| P/E Ratio | -151.85 |
|---|---|
| PEG | -111.32 |
| Price to Sales | 4.36 |
| Price to Book Ratio | 2.11 |
| Enterprise Value to Revenue | 3.77 |
| Enterprise Value to EBIT | 20.92 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$27.97 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cosmo N.V.
324 employees
CEO: Giovanni di Napoli
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that...